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A B S T R A C T
Bluetongue virus (BTV) is the prototype orbivirus (Reoviridae family, genus Orbivirus) consisting of more
than 24 recognized serotypes or neutralization groups. Recently, new BTV serotypes in goats have been
found; serotype 25 (Toggenburg Orbivirusor TOV), serotype 26 (KUW2010/02), and serotype 27 from
Corsica, France. KUW2010/02 has been isolated in mammalian cells but is not replicating in Culicoides
cells. TOVhas been detected in goats but could not been cultured, although TOV has been successfully
passed to naïve animals by experimental infection using viremic blood. Genome segments Seg-2[VP2],
Seg-6[VP5], Seg-7[VP7], and Seg-10[NS3/NS3a] expressing the respective TOV proteins were
incorporated in BTV using reverse genetics, demonstrating that these TOV proteins are functional in
BTV replication. Depending on the incorporated TOV proteins, in vitro replication is, however, decreased
compared to the ancestor BTV, in particular by TOV-VP5. Sheep and goats were experimentally infected
with BTV expressing both outer capsid proteins VP2 and VP5 of TOV, so-named ‘TOV-serotyped BTV’.
Viremia was not detected in sheep, and hardly detected in goats after infection with TOV-serotyped BTV.
Seroconversion by cELISA, however, was detected, suggesting that TOV-serotyped BTV replicates in small
ruminants. One goat was coincidentally pregnant, and the fetus was strong PCR-positive in blood samples
and several organs, which conclusively demonstrates that TOV-serotyped BTV replicates in vivo.
ã 2016 Elsevier B.V. All rights reserved.
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Bluetongue (BT) is listed as a ‘notiﬁable disease’ of ruminants by
the World Organization of Animal Health (OIE, 2014). The causing
pathogen bluetongue virus (BTV) belongs to the family Reoviridae,
genus Orbivirus (Mertens et al., 2005), and is transmitted between
ruminants, such as cattle, sheep, and goats, by bites of competent
Culicoides midges. Historically, 24BTV serotypes have been
recognized. Several nonvirulent BTVs have been detected by PCR
testing, like live-attenuated vaccine viruses for serotype 6 and 11
due to the increased alertness in Europe by the BT8 outbreak, (ISID
Promed mail, 2008, 2009). Indeed, vaccine related BTV6/net08 is
not virulent (Eschbaumer et al., 2010; van Rijn et al., 2012a),
whereas vaccine virus for serotype 11 has not been isolated (De* Corresponding author at: Central Veterinary Institute of Wageningen UR (CVI),
Department of Virology, P.O. Box 65, 8200 AB Lelystad, The Netherlands.
E-mail addresses: piet.vanrijn@wur.nl (P.A. van Rijn),
Sandra.vandewater@wur.nl (S.G.P. van de Water), mieke.maris@wur.nl
(M.A. Maris-Veldhuis), rene.vangennip@wur.nl (R.G.P. van Gennip).
http://dx.doi.org/10.1016/j.vetmic.2016.07.013
0378-1135/ã 2016 Elsevier B.V. All rights reserved.Clercq et al., 2009). In addition, new viruses have been identiﬁedas
BTV based on their genetic relationship, and are accepted as
additional BTV serotypes based on the serotype speciﬁc VP2
protein. Toggenburg orbivirus (TOV) has been accepted as BTV25
(Hofmann et al., 2008), KUW2010/02 (KUW)as BTV26 (Maan et al.,
2011), and a new BTVisolate from Corsica, France is considered as
BTV27 (Jenckel et al., 2015; Zientara et al., 2014).
BTV consists of ten linear double-stranded RNA genome
segments, Seg-1–10, encoding structural proteins VP1–VP7, and
nonstructural proteins NS1, NS2, NS3/NS3a. Recently, NS4 and a
novel uncharacterized protein S10-ORF2 have been discovered
(Belhouchet et al., 2011; Ratinier et al., 2011; Roy, 2008; Stewart
et al., 2015). The virus particle is composed of three protein layers
of which the outer shell is formed by VP2 and VP5,indicating an
important role in attachment, virus entry and host tropism.The
constellation of the BTV genome is highly ﬂexible (Shaw et al.,
2013; van Gennip et al., 2012b). So-named ‘serotyped’ BTVsby
exchange of Seg-2[VP2] and Seg-6[VP5] have been generated for
many serotypes by use of reverse genetics (Boyce et al., 2008;
Feenstra et al., 2015; Nunes et al., 2014; van Gennip et al., 2012a).
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reported (van Rijn et al., 2012b), but horizontal transmission is
signiﬁcant for KUW (Batten et al., 2014; Batten et al., 2012). KUW
was isolated and cultured on mammalian cells but did not
replicatein midge cells (Batten et al., 2014). Apparently, Seg-1
[VP1], 2[VP2], 3[VP3], 6[VP5] and Seg-7[VP7] of KUWare involved
in cell tropism (Pullinger et al., 2016). TOV has been detected by
PCR in goats, whereas the virus has not been found in sheep and
cattle (Chaignat et al., 2010). This suggests a strong host tropism,
although host preference by the competent insect vector, if any, for
transmission of TOV cannot be excluded (Chaignat et al., 2009;
Hofmann et al., 2008). TOV could not be cultured in vitro (Chaignat
et al., 2010), although experimental infection of goats and sheep
was successful with viremic blood (Chaignat et al., 2009; Vogtlin
et al., 2013).
Here, BTV expressing several TOV proteins were generated
using reverse genetics including BTV expressing VP2 and VP5, so-
named ‘TOV-serotyped BTV’. BTV expressing TOV proteins were
studied in vitro as well as in vivo by infection of sheep and goats.
2. Materials and methods
2.1. Cell lines and virus
BSR cells (a clone of baby hamster kidney cells (Sato et al., 1977)
were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Invitrogen) containing 5% fetal bovine serum (FBS), 100 IU/ml
penicillin, 100 mg/ml streptomycin and 2,5 ug/ml Amphotericin B.
All viruses in this study were generated by reverse genetics (van
Gennip et al., 2012b).
2.2. T7 plasmids and in vitro synthesis of full length run-off RNA
transcripts
Genome segments of BTV1 and 6 have been described
previously (van Gennip et al., 2012b). Open reading frames (ORFs)
of genome segments of TOV (Hofmann et al., 2008) were ﬂanked by
nontranslated regions (NTRs) of the respective genome segments
of BTV8/net06 (Anthony et al., 2010). Genome segments were
synthesized by Genscript Corporation (Piscataway, NJ, USA).
Plasmids based on pUC57 containing cDNA between theT7
promoter and a unique restriction enzyme site for run-off
transcription were maintained in E. coli DH5a, and were puriﬁed
using the QIA ﬁlter Plasmid Midi Kit (Qiagen). Capped run-off RNA
transcripts were synthesized, and cleaned using MEGAclear
columns (Ambion) and stored at 80 C (van Gennip et al., 2012b).
2.3. Rescue of BTV expressing TOVproteins
Viruses were generated as described (van Gennip et al., 2012b).
Brieﬂy, monolayers of 105 BSR cells per 2 cm2 were transfected
with 600 ng of equimolar amounts of RNAs encoding VP1, VP3, VP4,
NS1, NS2 and VP6/NS4 followed by transfection with the indicated
set of 10 run-off RNA transcripts after 18–20 h. Supernatants
containing virus were harvested from monolayers developing
cytopathogenic effect (CPE) at 48–72 h after the second transfec-
tion. Rescue ofvirus was conﬁrmed by infection of fresh BSR
monolayers, and virus stocks were prepared and stored at 80 C.
Infection was monitored by cytopathogenic effect (CPE) and
immunostaining with a-VP7 monoclonal antibody (MAb) pro-
duced by ATCC-CRL-1875 according to the immunoperoxidase
monolayer assay (IPMA) (Wensvoort et al., 1988). Seg-2[VP2], Seg-
6[VP6],Seg-7[VP7], and Seg-10[NS3/NS3a] were conﬁrmed by
ampliﬁcation with appropriate primers followed by sequencing
parts of Seg-2 (S2-genotyping) and Seg-6, and entire Seg-7 and 10
(van Gennip et al., 2012a). Virus growth was determined aspreviously described (van Gennip et al., 2014). Brieﬂy, monolayers
of BSR cells (5 105) in 2 cm2 wells were infected with virus at a
multiplicity of infection 0.01. Virus was attached for 1.5 h at 37 C.
Unattached virus was removed by washing with PBS, and fresh
medium was added. This time point was set as 0 h post infection.
Incubation was continued for the indicated time points. Virus titers
were determined by endpoint dilution in BSR cells and expressed
as tissue culture infective dose (10logTCID50/ml).
2.3. Animal experiments
All experiments with live animals were performed under the
guidelines of the European Community (86/609). Described animal
experiments were approved by the Committee on the Ethics of
Animal Experiments of the Central Veterinary Institute (permit
numbers 2011-003 and 2012-029). Female animals of 6–24 months
old and free of BTV and BTV-antibodies were commercially
sourced from a Dutch farm.
Body temperature and clinical signs were recorded throughout
the experiments. Clinical signs were recorded according to the
clinical score table (van Gennip et al., 2012b). Samples of EDTA-
blood and serum were frequently collected.Serum samples were
analysed by the competition ELISA (cELISA) (ID.VET).EDTA-blood
samples were analysed by the panBTV-PCR test (van Rijn et al.,
2012b). Selected EDTA-blood samples were subject for conﬁrma-
tion of Seg-2 as described above.
2.3.1. Experiment 1. infection with TOV-serotyped BTV6
Two Blessumer sheep were injected intramuscularly (im) in the
neck as previously described (van Gennip et al., 2012a) with 1 ml of
105 TCID50/ml ‘TOV-serotyped’ BTV6(BTV6[VP2,VP5]25) on day 0 (0
dpi). After three weeks (21 dpi), sheep were injected again with
1 ml of 105 TCID50/ml of TOV-serotyped BTV6, and were monitored
for another three weeks. The experiment was terminated at day 42.
Four Blessumer sheep were similarly injected with 1 ml of 101.4
TCID50/ml rgBTV6. These sheep were subjected to challenge with
virulent BTV8on day 21 (van Gennip et al., 2012a), and comparison
with TOV-serotyped BTV6 was no longer justiﬁed.
2.3.2. Experiment 2. infection with TOV-serotyped BTV1
Four Texeler sheep and two female dairy goats were allocated in
one group of two sheep and two goats, and one group of two sheep.
On day 0, 21 and 42, the group of two sheep and two goats was
injected intravenously (iv) and subcutaneously (sc) with 1 ml of
105 TCID50/ml of TOV-serotyped BTV1 (BTV1[VP2,VP5]25) per
route of injection. The group of two sheep was similarly injected
with BTV1 generated by reverse genetics (rgBTV1) (van Gennip
et al., 2012a). Subcutaneous injection was performed between the
shoulder blades left and right from the spinal cord. The experiment
was terminated at day 63.
3. Results
3.1. Rescue of BTV expressing TOV proteins
Since complete sequences of genome segments of TOV were not
available, open reading frames (ORF) encoding TOV proteins were
ﬂanked by nontranslated sequences of the respective genome
segments of BTV8/net06. BTV expressing TOV proteins were
rescued using chimeric RNA transcripts encoding TOV proteins
VP2, VP5, VP7 and NS3/NS3a (Table 1). Exchange of Seg-2[VP2]25
and Seg-6[VP5]25 in rgBTV6 resulted in TOV-serotyped BTV6
demonstrating that both outer shell proteins are functional in virus
replication in vitro. BTV6[VP2]25 could not be rescued and is
apparently not viable. Similarly, rgBTV1 with Seg-2[VP2] 25, BTV1
[VP2]25, was not viable. All other combinations of chimeric Seg-2,
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Fig. 1. Growth curves of BTV expressing TOV proteins. Conﬂuent BSR monolayers were infected in duplicate by indicated viruses with MOI of 0.1 Total virus titers were
determined at 0, 6, 24, 48, 72 and 96 h post infection and expressed as tissue culture infective dose (10log TCID50/ml). A. growth curve of serotyped BTV6 viruses. B. Growth
curve of rgBTV1 expressing TOV proteins.
Table 1
BTV expressing TOV proteins. BTV with genome segments containing the open reading frame (ORF) of the respective TOV proteins were rescued by reverse genetics (+).BTV
with chimeric Seg-2[VP2]25 could not be rescued (). Except for BTV1[VP2]25 and BTV6[VP2]25 (nd), virus rescuewas conﬁrmed by infection of fresh monolayers by induction
of cytopathogenic effect (CPE) and immunostaining with VP7 directed MAb (IPMA)(+).
Name Chimeric segment with ORF of TOV Rescue CPE IPMA
rgBTV6 – + + +
BTV6[VP2]25 2 – nd nd
TOV-serotyped BTV6 2,6 + + +
rgBTV1 – + + +
BTV1[VP2]25 2 – nd nd
BTV1[VP5]25 6 + + +
BTV1[VP7]25 7 + + +
BTV1[NS3/NS3a]25 10 + + +
TOV-serotyped BTV1 2,6 + + +
BTV1[VP7,NS3/NS3a]25 7,10 + + +
BTV1[VP5,VP7,NS3/NS3a]25 6,7,10 + + +
BTV1[VP2,VP5,VP7,NS3/NS3a]25 2,6,7,10 + + +
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backbone are functional (Table 1). Note, BTV1 expressing NS3/
NS3a protein of TOV or both outer capsid proteins have been
published previously (Feenstra et al., 2016); (Nunes et al., 2014).
We conclude that VP2, 5, 7 and NS3/NS3a of TOV are functional in
BTV replication in vitro.
3.2. Growth kinetics of BTV expressing TOV proteins
TOV-serotyped BTV6 was delayed in virus growth, and the ﬁnal
virus titer was lower than of rgBTV6, in contrast to serotyped
rgBTV6 variants for serotype 1 and 8 (Fig. 1A) (van Gennip et al.,
2012a). Growth of TOV-serotyped BTV1 was also decreased
compared to ancestor rgBTV1 (Fig. 1B). Apparently, TOV outer
shell proteins reduce virus replication in vitro, irrespective of the
BTV backbone (Fig. 1). Reduced growth was most obvious for
BTV1expressing TOV-VP5 ([VP5]25. Expression of multiple TOV
proteins further reduced BTV replication, whereas BTV1[VP7]25
and BTV1[NS3/NS3a]25 were not obviously delayed in virus
growth. BTV1[VP2,VP5,VP7,NS3/NS3a]25 showed the strongest
reduction in virus growth, indicating a negative accumulation
on in vitro virus replication by TOV proteins.
3.3. Experimental infection with TOV-serotyped BTV
Two sheep, sh4325 and sh4326, were intramuscularly (im)
infected with 10*5 log TCID50 of TOV-serotyped BTV6, and
compared to vaccination with rgBTV6 (sh4301-sh4304) (van
Gennip et al., 2012a). No clinical signs nor elevated body
temperature were observed for sheep infected with TOV-serotyped
BTV6. In contrast to BTV6 vaccinated sheep (van Gennip et al.,
2012a), both sheep infected with TOV-serotyped BTV6 remained
PCR-negative (not shown). Sh4325 showed 40–50% blocking from
7 to 21 dpi, whereas sh4326 hardly developed VP7 Abs (Fig. 2). In
contrast, vaccination with rgBTV6 resulted in 100% blocking.
After the second vaccination with TOV-serotyped BTV6on 21 dpi,
no viremia was detected by the panBTVPCR-testin both sheep (not
shown). However, sh4325 seroconverted to >90%at 7 days post
booster (28 dpi) up to 42 dpi, the end of the experiment (Fig. 2).
Sh4326 also seroconverted slowly to a peak of 60% at 7–10 days-20
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Fig. 2. Experimental infection of sheep with TOV serotyped BTV6. On day 0 (0 dpi), two s
serotyped BTV6. Similarly, four sheep were infected with 1 ml of 101.4 TCID50/ml rgBT
serotyped BTV6 on 21 dpi (arrow), whereas rgBTV6 infected sheep were subjected to an
the cELISA and theblocking percentage is displayed as 100-value.after the booster (28–30 dpi), and then slowly declined to 30% at
42 dpi. Sheep vaccinated with rgBTV6 were subjected to challenge
with virulent BTV8, and comparison was no longer justiﬁed (van
Gennip et al., 2012a).
To initiate and study in vivo replication, small ruminants were
repeatedly infected subcutaneously (sc) and intravenously (iv)
with TOV-serotyped BTV1. Sh6400 and sh6401 served as controls
and were similarly infected with ancestor virus rgBTV1 (Fig. 3).
Sh6400 developed a low viremia suggesting replication of rgBTV1.
Sh6401 did not show viremia by the panBTV PCR test after the ﬁrst
infection (Fig. 3A). Sheep sh9396 and sh9397 infected with TOV-
serotyped BTV1 remained PCR negative during the whole
experiment, whereas goats g9397 and g9399 showed weak PCR-
signals for several days. This indicates virus replication of TOV-
serotyped BTV1 in goats and not in sheep. Sh6400 seroconverted
quickly to 90% at 10 dpi, whereas seroconversion in sh6401 peaked
to 60% at 3–10 dpi and then declined to 30% at 21 dpi (Fig. 3B).
Remarkably, experimental infection with TOV-serotyped BTV1
resulted in a higher seroconversion in sheep than in goats, despite
the absence of viremia in sheep.
After reinfection on 21 dpi, sh6401 had afever (>40.5 C) for
three successive days from 22 to 24 dpi (not shown). In addition, a
low viremia by panBTV PCR testing was determined at 35 dpi,
14 days after reinfection for the ﬁrst time (Fig. 3A). This indicates
replication of rgBTV1 in sh6401 after reinfection. On the same day,
sh6400 had a small increase in viremia but no elevated
temperature. Similarly, reinfection of goats with TOV-serotyped
BTV1 had a small increase in viremia. Again, sh6396 and sh6397
remained PCR negative. All animals seroconverted to 100% after
this reinfection (Fig. 3B).
The third infection at 42 dpi did not induce clinical signs or
elevated body temperature (not shown), and viremia was further
declining to negative in all animals at 63 dpi, the end of the
experiment (Fig. 3A). Increase in antibody titer could not be
measured by cELISA with undiluted sera, but serial two-fold
dilutions of sera collected at 21, 42, and 63 dpi showed increase of
VP7-Abs after every infection (not shown).
The experimentally infected animals were supposed not to be
pregnant, but g6399 aborted at 55 dpi. The fetus was estimated
11–12 weeks old. Foetal blood, spleen and lung were high PCR22 24 26 28 30 32 34 36 38 40 42
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Fig. 3. Experimental infection of sheep and goats with TOV-serotyped BTV. On day 0, animals were infected intravenously and subcutaneously with 1 ml of 105 TCID50/ml
TOV-serotyped BTV1 per route. On day 21 and 42, infection was repeated with the same dose and routes (arrows). Two sheep were similarly infected with rgBTV. A. BTV was
determined by the panBTV-PCR test. Negative PCR results were set on Cp = 45. B. BTV VP7 directed antibodies in serum samples were detected with the panBTVcELISA. The
blocking percentage is displayed as 100-value.
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lesions were seen. Apparently, TOV-serotyped BTV1 has vertically
transmitted and caused a high viremia in the fetus.
Summarizing, TOV-serotyped BTV replicated in small rumi-
nants, although viremia in sheep was not conclusively detected.
However, replication of TOV-serotyped BTV most likely occurred as
demonstrated by a rapid and high seroconversion. Convincingly, in
vivo replication of TOV-serotyped BTV was shown in an aborted
goat fetus by a high PCR-signal in blood and several organs.
4. Discussion
Novel serotypes belonging to the BTV species (family Reovir-
idae, genus Orbivirus) has been proposed and generally accepted as
BTV serotype 25–27, despite of atypical virus characteristics.
BTV25 or Toggenburg Orbivirus (TOV) could not be cultured in vitro
(Planzer et al., 2011). Therefore, natural BTV/TOV reassortants
cannot be generated in doubly infected cells to proof their genetic
relationship. We here used reverse genetics to incorporate TOV
proteins in BTV, and demonstrated their functionality in vitro and
in vivo.
Structural TOV proteins VP2, VP5 and VP7 are functional in BTV
replication in vitro, conﬁrming that TOV is a member of the BTV
species of the Orbivirus genus. For example, BTV1[VP7]25 contains
TOV-VP7 interacting with subcore protein VP3 and outer capsidproteins VP2 and VP5 of BTV1. In contrast, TOV-VP2 protein could
not be incorporated solely in BTV1 or BTV6, however, it forms a
functional outer capsid with TOV-VP5 in both BTV backbones. This
is in agreement with previous ﬁndings for the rgBTV1 backbone
(Nunes et al., 2014). Lacking cultured TOV, we propose that BTV
expressing both outer capsid proteins of TOVcan represent the
25thBTV serotype.
Previously, nonstructural protein NS3/NS3a of TOV and KUW
have been incorporated in BTV1 (Feenstra et al., 2016). Since NS3/
NS3a is not essential for virus replication (van Gennip et al., 2014),
the requirement of this protein in virus replication could not be
studied. However, the role of NS3/NS3a of TOV in virus release was
shown (Feenstra et al., 2016). Others have extensively studied
BTV1/KUW reassortants, and conclusively demonstrated that all
proteins of KUW (BTV26) are functional inBTV replication in
mammalian cells (Pullinger et al., 2016).
TOV-VP5 protein reduced virus growth more than the other
studied TOV proteins VP2, VP7, and NS3/NS3a (Fig.1). Multiple TOV
proteins further reducesvirus growth compared to BTV1 express-
ing one TOVprotein. Except for the combination of Seg-2, 6, and 7,
BTV1/KUW reassortants with multiple segments were not studied
(Pullinger et al., 2016). Although the KUW isolate was cultured in
mammalian cells, ‘synthetic’ KUW could not be rescued, suggest-
ing reduction of virus growth by multiple ‘synthetic’ genome
segments of KUW in rgBTV1(Pullinger et al., 2016). Since the
150 P.A. van Rijn et al. / Veterinary Microbiology 192 (2016) 145–151ancestor TOV could not be cultured at all (Planzer et al., 2011), we
assume that incorporation of more TOV proteins in BTV will further
reduce virus growth or will hamper rescue of complete synthetic
TOV. Still, reverse genetics can be used to study TOV proteinsin
virus replication in vitro by rescue of rgBTV1 expressing TOV
proteins one by one as here described in order to elucidate the
inability of TOV to replicate in vitro.
We have here limited our research on TOV proteinsimportant
for diagnostics and vaccine development, namely VP7 (ELISA), VP2
and VP5 (serotype speciﬁcity), and Seg-10[NS3/NS3a] (molecular
and serologydiagnostics (Tacken et al., 2015; van Rijn et al., 2012b,
2013). TOV-serotyped BTVs expressing both outer capsid proteins
were studied in vivo by experimental infection of sheep and goats
(Figs. 2 and 3). Infection with TOV-serotyped BTV did not result in
viremia in sheep, irrespective of the backbone and the route of
inoculation. Despite the small numbers of sheep in two experi-
ments, four sheep were infected via different routes and viremia
was not detected in sheep. On the other hand, seroconversion was
signiﬁcant (50%) in the VP7 cELISA, which suggests virus
replication of TOV-serotyped BTV, since subcutaneous injection
of equal amounts of inactivated non-adjuvanted BTV8 did not
induce seroconversion (Feenstra et al., 2014b). Likely, replication of
TOV-serotyped BTV in sheepis very low, and does not result in
viremia although VP7 Abs were raised. Similar results -serocon-
version and no detectable viremia – were observed for the novel BT
DISA vaccine (Feenstra et al., 2014a,b; Feenstra et al., 2015). DISA
vaccine virus is delayed in virus growth in mammalian cells in vitro
due to the lack of virus release related to NS3/NS3a expression (van
Gennip et al., 2014). TOV serotyped BTV is reduced in virus growth,
likely by less efﬁcient infection of cells (Figs. 1 and 2). We suppose
that both disturbed processes  infection or excretion  reduce
virus propagation in vivo leading to lack of viremia. However, the
low level of virus replication is sufﬁcient for the induction of
antibodies as determined by the VP7 cELISA.
In contrast to sheep, infection of goats with TOV-serotyped
BTV1 resulted in a low viremia. Seroconversion in sheep, however,
was higher than in goats after the ﬁrst infection. Apparently, sheep
react faster and stronger to infection (Fig. 3). Possibly, this quick
response also contributes to the lack of viremia in sheep.
Remarkably, BTV1 infection of sheep sh6400 and sh6401 resulted
in a different response. Likely, infection by rgBTV1 is very
inefﬁcient, despite a virus titer of 10*5 TCID50/ml determined on
BSR cells. Infection of sh6401 seemed to have failedas measured by
the negative PCR and very weak seroconversion. The second
infection of sh6401 with rgBTV1 resulted in viremia which was
very similar to the ﬁrst rgBTV1 infection of sh6400. All six animals
iv and sc inoculated with BTV1-based viruses seroconverted
rapidly and completely (100%) after reinfection. Altogether,
replication of TOV-serotyped BTV was indirectly shown by the
strong seroconversion but also directly by the PCR positivity of
goats. Furthermore, fetal infection byTOV-serotyped BTV1 was
found and there was a high viremia as measured by low Cp values
of 13–15 in several organs and fetal blood. Passing of virus to the
fetus as well as the high viremia convincingly demonstrated
replication of TOV-serotyped BTV in this goat.
Sheep remained PCR negative after infection with TOV-
serotyped BTVs, whereas infected goats had a low viremia. This
suggests host preference for goats which is in agreement with
observations in the ﬁeld where mixed farms affected by TOV
showed a very low seroprevalence in sheep and cattle compared to
goats (Chaignat et al., 2010). Our data suggest that this host
preference is determined by TOV outer shell proteins VP2 and VP5.
Further research is needed to identify genome segments and
their expressed proteins involved in host and cell tropism of TOV.
Ultimately, this research will lead to cultured TOV as a
‘true’representative of the 25th serotype within the BTV species.Conﬂict of interest
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